Siegfried

Well on track to meet FY26 guidance

21/08/26 -"Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues generated by the acquisitions closed on May 1st, 2026. The ..."

PDF page sample
Pages
57
Language
English
Published on
21/08/26
Download
You may also be interested by these reports :
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...
21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...
21/08/26
Moderna’s mRNA cancer vaccine combined with Merck’s Keytruda does look like a game changer for the wider pharma industry. It looks like a decisive ...
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO